Clinical Trials Logo

Clinical Trial Summary

It is been known for at least 20 years that the hemodynamic data, the amount of exercise performed as well as symptoms on the treadmill, has significant value to the perfusion stress testing. When a pharmacologic stress test is performed (and adenosine stress test over 4-6 minutes), this hemodynamic data is lost. Because of this loss of valuable data, it is felt that there is also a loss of significant prognostic data as well. With the advent and FDA release of Regadenoson in a rapid injection form (over 10 seconds), it is thought that the combination of both exercise stress testing and pharmacologic testing in subjects that do not achieve 85% in a maximal predicted heart rate may be a viable stress testing option. The purpose of this study is to look at using the drug, regadenoson, with exercise stress testing; and the side effect symptoms that may be experienced by individual subjects using this combination.


Clinical Trial Description

A nuclear stress test has been recommended for a patient by their doctor. This test helps to detect significant blockages in the artery to the heart. The test involves the patient walking on a treadmill until their heart rate reaches 85% of their age-determined maximal predicted heart rate. If the patient needs to stop walking for any reason (tiredness, chest pain, shortness of breath or dizziness) prior to reaching the 85% of their maximal heart rate, then the test becomes inaccurate and blockages can be missed. Nonetheless, the information that we gain from the patient walking remains valuable. If the subject does not reach 85%, the usual procedure is to re-do the test where the subject would not walk on the treadmill, but would be injected with a pharmacologic agent (drug) which dilates their blood vessels. This would allow us to obtain an accurate picture about any blockages in the blood vessels. By doing the "drug" test alone, we lose the important information gained by the treadmill test. In the present study the subject will be asked to walk on the treadmill and near the end of the walk, if they do not reach 85%, then the "drug" will be given to the patient. Regadenoson is FDA approved for drug stress testing. Regadenoson (versus one of the other pharmacological agents) will be given at a dose of 400 mcg, will be infused over 10 - 20 seconds followed by standard flushing solution, and then the infusion of a radiotracer (the FDA approved method of administration) will be given for nuclear imaging. The entire intravenous procedure takes 30 seconds. The subject will then undergo 5 minutes of standard observation/monitoring post infusion administration. Standard nuclear stress imaging will then follow. By doing this, we will obtain all the important information from the exercise portion of this test and maintain the accuracy to detect blockages. By doing the study in this manner, we will be able to save the subject time and obtain more information about the heart than either test individually. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01026012
Study type Interventional
Source University of Maryland, Baltimore
Contact
Status Completed
Phase N/A
Start date December 2009
Completion date September 2010

See also
  Status Clinical Trial Phase
Completed NCT04577430 - Effects of Dexmedetomidine on Cardiac Electrophysiology in Patients Under General Anesthesia During Perioperative Period N/A
Recruiting NCT01881945 - Validation of Study in Respiratory Physiology and it Interactions N/A
Terminated NCT04538079 - Non-invasive Objective Assessment of Hemodynamics in Preterm Neonates
Recruiting NCT05662995 - Point-of-care Ultrasound Abnormalities in Early Onset Preeclampsia N/A
Recruiting NCT04455477 - Nesiritide for Ventilated Congestive Heart Failure
Recruiting NCT05698277 - Automated Fetal Cardiac Function in Babies Affected by Heart Diseases
Completed NCT01352403 - Severe Obesity: Bariatric Surgery vs. Life-Style-Intervention N/A
Completed NCT00970463 - Cardiac Function and Morphology Evaluated by Magnetic Resonance Imaging in Growth Hormone Deficiency and Acromegaly N/A
Completed NCT01443780 - Intervention With Selenium and Q10 on Cardiovascular Mortality and Cardiac Function in the Elderly Population in Sweden N/A
Completed NCT04529187 - Effect of Midazolam and Dexmedetomidine on Heart Function - A Randomized MRI-based Study. Phase 4
Recruiting NCT04287114 - Cardiac Stroke Volume at Rest and During Different Exercise Intensities N/A
Withdrawn NCT00882622 - Effect of Remote Ischemic Preconditioning on Cardiac Function After Cardiac Surgery Phase 1
Recruiting NCT03805776 - Intermittent Fasting in Dyslipidemia N/A
Recruiting NCT05962190 - Short-term Fat Overfeeding on the Effects of Liver Metabolism N/A
Completed NCT04629937 - Evaluation of Whole-body CZT Camera in Gated Tomographic Radionuclide Angiography N/A
Completed NCT03445221 - Preoperative Immunonutrition and Cardiac Patients Phase 2/Phase 3